The Postoperative Radiotherapy after Breast Conserving Surgery or Mastectomy in N1 Breast Cancer Patients: A Prospective, Multicenter, Phase III Clinical Trial (PORT-N1)

Seoul National University Hospital0 个研究点目标入组 1,106 人开始时间: 待定最近更新: 2023年12月19日

适应症

试验速览

暂无简介。

•Patients aged 19 years or older.
•-A female patient who underwent breast-conserving surgery or mastectomy for invasive breast cancer.
•-Patient with stage pN1 after surgery on histopathologic examination.
•** However, if mastectomy was performed, 5 or more nodes should be resected in the case of 1 positive node, and axillary lymph node dissection (ALND) should be performed in case of 2 or 3 positive nodes.
•-Patients undergoing or planning to undergo hormone therapy in the case of hormone receptor positive.
•-Patients who have received or are expected to undergo targeted therapy in the case of HER-2 positive.
•-Patients with Eastern Cooperative Oncology Group (ECOG) Scale 0-2.
•-Patients who agreed to participate in the study.

•-Patients who have received prior [neoadjuvant] chemotherapy.
•-Patients receiving radiation therapy for salvage or palliative purposes.
•-Patients with stage T4.
•-Patients with ipsilateral supraclavicular and internal mammary lymph node metastases or distant metastases.
•-Male breast cancer patient.
•-Patients who have previously received radiation therapy to the ipsilateral breast or supraclavicular region.
•-Patients having a history of cancer other than thyroid cancer, cervical carcinoma in situ, or skin cancer.
•-Patients diagnosed with ductal breast carcinoma in situ, lobular carcinoma in situ, phyllodes, metaplastic cancer, or benign tumors based on histological diagnosis.

发起方